238 related articles for article (PubMed ID: 35991054)
1. PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review.
Lin C; Li X; Qiu Y; Chen Z; Liu J
Front Public Health; 2022; 10():885001. PubMed ID: 35991054
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.
Luo J; Feng J; Liu C; Yang Z; Zhan D; Wu Y; Pan L; Zhang L
J Int Med Res; 2022 Sep; 50(9):3000605221121940. PubMed ID: 36171723
[TBL] [Abstract][Full Text] [Related]
4. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
5. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
Kotwal A; Haddox C; Block M; Kudva YC
BMJ Open Diabetes Res Care; 2019; 7(1):e000591. PubMed ID: 30899528
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
Goff CB; Plaxe SC; White W; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1259-1263. PubMed ID: 36734125
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
Qiu J; Luo S; Yin W; Li X; Zhou Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):49-58. PubMed ID: 36935177
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
11. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
12. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
14. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
Fujiwara M; Shimizu M; Okano T; Maejima Y; Shimomura K
Front Public Health; 2023; 11():1264056. PubMed ID: 38106883
[TBL] [Abstract][Full Text] [Related]
16. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
Harsch IA; Konturek PC
Wiad Lek; 2018; 71(5):945-948. PubMed ID: 30176620
[TBL] [Abstract][Full Text] [Related]
17. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
Abdullah HMA; Elnair R; Khan UI; Omar M; Morey-Vargas OL
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451458
[TBL] [Abstract][Full Text] [Related]
18. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Ishi A; Tanaka I; Iwama S; Sakakibara T; Mastui T; Kobayashi T; Hase T; Morise M; Sato M; Arima H; Hashimoto N
Endocr J; 2021 May; 68(5):613-620. PubMed ID: 33790087
[TBL] [Abstract][Full Text] [Related]
19. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
Mae S; Kuriyama A; Tachibana H
J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
Tsang VHM; McGrath RT; Clifton-Bligh RJ; Scolyer RA; Jakrot V; Guminski AD; Long GV; Menzies AM
J Clin Endocrinol Metab; 2019 Nov; 104(11):5499-5506. PubMed ID: 31265074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
